Evidence map›Paper›PMID 28575434›Full record

ArticleEndocrinology2017

Incretin-Based Therapies: Revisiting Their Mode of Action.

Brian T Layden, Barton Wicksteed, Franck Mauvais-Jarvis

Abstract readComment
In one paragraph

Article in Endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Brian T LaydenDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, Illinois 60612.
Barton WicksteedDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, Illinois 60612.
Franck Mauvais-JarvisDiabetes Research and Gender Medicine Laboratory, Section of Endocrinology and Metabolism, Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112.

Funding

Pilot and Feasibility ProgramP30DK020595 · NIDDK · UNIVERSITY OF CHICAGO · PI Matthew J Brady · 2013 to 2026
$20.9M
The function and regulation of the novel pregnancy-specific hexokinase HKDC1R01DK104927 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LAYDEN, BRIAN THOMAS, REDDY, TIMOTHY E · 2015 to 2024
$7.2M
Targeting the estrogen receptor-α to protect functional β-cell mass in womenR01DK074970 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI Franck Mauvais-Jarvis · 2007 to 2026
$6.0M
Repurposing estrogens to improve pancreatic islet transplantationR01DK107444 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI MAUVAIS-JARVIS, FRANCK · 2016 to 2019
$1.5M
Role of Nutrient Sensing Receptors for the Gut Microbiota in MetabolismI01BX003382 · VA · JESSE BROWN VA MEDICAL CENTER · PI LAYDEN, BRIAN THOMAS · 2017 to 2025
–
Role of Short Chain Fatty Acids and their Receptors in Islet FunctionIK2BX001587 · VA · JESSE BROWN VA MEDICAL CENTER · PI LAYDEN, BRIAN THOMAS · 2012 to 2016
–
BLRD VA I01 BX003382BLRD VA IK2 BX001587NIDDK NIH HHS P30 DK020595NIDDK NIH HHS R01 DK074970NIDDK NIH HHS R01 DK104927NIDDK NIH HHS R01 DK107444
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dipeptidyl-Peptidase IV InhibitorsIncretinsDiabetes Mellitus, Type 2Glucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHypoglycemic AgentsIncretins

Identifiers

PMID28575434
PMCPMC5460946

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.